This week, we speak with Len Liptak, CEO of ProSomnus Sleep Technologies, which announced a $168 million combination with Lakeshore Acquisition I Corp. (Nasdaq: LAAA), in May.
ProSomnus has developed a new device to treat obstructive sleep apnea that disrupts the need for its millions of sufferers to be connected to ventilators at night. Len explains how the COVID-19 pandemic increased the need for sleep apnea treatments, and how this deal will help power its continued commercialization.
Lakeshore I CEO and Chairman Bill Chen joins to tell us why it was important that ProSomnus is already generating revenue and how SPACs can still compete for quality targets in the current market.
SPACInsider